We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Oncology

Journal Scan / Research · October 03, 2019

Ibrutinib Plus Lenalidomide and Rituximab Treats Relapsed or Refractory DLBCL



Additional Info

Ibrutinib Plus Lenalidomide and Rituximab Has Promising Activity in Relapsed/Refractory Non-Germinal Center B-Cell-Like DLBCL
Blood 2019 Sep 26;134(13)1024-1036, A Goy, R Ramchandren, N Ghosh, J Munoz, DS Morgan, NH Dang, M Knapp, M Delioukina, E Kingsley, J Ping, DM Beaupre, JK Neuenburg, J Ruan

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading